SlideShare une entreprise Scribd logo
1  sur  15
Anabolic Response to Skeletal Loading in Mice with Targeted Disruption of Pleiotrophin Gene C. Kesavan   and S. Mohan  JLP VA Medical Center, Loma Linda Univ Loma Linda, CA, 92357 ASBMR 2008
Acknowledgements   ,[object Object],[object Object],The authors have no conflict of interest
Load Load Good Responder Poor Responder Skeletal Response to Loading Differs in  Different Individuals
Variation in skeletal response to loading is genetically determined 0.00 5.00 10.00 15.00 20.00 6 7 8 9 Load (N) % Increase in vBMD  vs unloaded bone Four point  bending device C57BL/6J C3H/HeJ Four point  bending Increases BMD in C57BL but not in C3H mice P<0.001 Kesavan et al., 2005 P<0.01
ML increases pleiotrophin (PTN) expression-Whole genome microarray analysis PTN signals through  β -catenin and PI3K  PTN expression  level ( arbitrary  units) p<0.0001 Xing et al., 2005 PTN/HB-GAM/OSF Syndecan Rprp ζ β -catenin PI3K Proliferation/survival/Migration
Time course changes in PTN expression in the loaded bones of C57BL Mice A p<0.05 vs. 2- and 4- days of loading (One-way ANOVA)   p<0.05 p<0.001 p<0.0001 Days (Duration) Fold increase in PTN  vs. unloaded bones A
Greater PTN expression in response to ML in good responder  C57BL versus poor responder C3H mice  Mean ± SD; N = 6 0 2 4 6 8 10 C57BL C3H Fold increase in PTN  vs. unloaded bones P<0.0001 P<0.05 P<0.05
Hypothesis ,[object Object]
9N load produces equivalent amount of strain in the tibia of PTN KO and  littermate control mice ,[object Object],[object Object],[object Object],[object Object],Mean  ± SD,  N = 7 Control PTN KO
Skeletal changes in response to loading in PTN KO and control mice *p<0.05 vs. unloaded bones, N = 7  Percent increase vs.  unloaded bones  * * * * * *
Micro-CT analysis of skeletal response to loading Control  PTN KO Unloaded Loaded Mean  ± SD,  N = 7 BV/TV (%) 3.88  ± 2.6 Tb.N (1/mm) 1.56  ± 0.76 Tb.Th (mm) 0.037 ± 0.0.01 Tb.S (mm) 0.76  ± 0.28 BV/TV (%) 2.81  ± 1.5 Tb.N (1/mm) 1.61  ± 0.36 Tb.Th (mm) 0.036 ± 0.0.01 Tb.S (mm) 0.57  ± 0.21
Greater midkine expression in response to ML in PTN KO and Control mice N=6 Fold increase vs.  unloaded bones  P<0.05 P<0.05 P<0.001
Summary ,[object Object],[object Object],[object Object],[object Object]
Conclusions ,[object Object],[object Object]
Thank you Skeletal  Un loading Skeletal Loading

Contenu connexe

En vedette

portafolio de ntics
portafolio de nticsportafolio de ntics
portafolio de nticsdanita345
 
Tallerfinalword2222222222222222
Tallerfinalword2222222222222222Tallerfinalword2222222222222222
Tallerfinalword2222222222222222tokitha
 
Practica
PracticaPractica
Practicatokitha
 
Presentación maratón xunqueira 2011
Presentación maratón xunqueira 2011Presentación maratón xunqueira 2011
Presentación maratón xunqueira 2011ceipvidalportela2
 

En vedette (6)

portafolio de ntics
portafolio de nticsportafolio de ntics
portafolio de ntics
 
Electrocardiograma
ElectrocardiogramaElectrocardiograma
Electrocardiograma
 
Tallerfinalword2222222222222222
Tallerfinalword2222222222222222Tallerfinalword2222222222222222
Tallerfinalword2222222222222222
 
Practica
PracticaPractica
Practica
 
Cells overveiw
Cells overveiwCells overveiw
Cells overveiw
 
Presentación maratón xunqueira 2011
Presentación maratón xunqueira 2011Presentación maratón xunqueira 2011
Presentación maratón xunqueira 2011
 

Similaire à Asbmr Ptn 2008 082008

2020 OA Vision: Emerging Therapeutics on the OA landscape
2020 OA Vision: Emerging Therapeutics on the OA landscape2020 OA Vision: Emerging Therapeutics on the OA landscape
2020 OA Vision: Emerging Therapeutics on the OA landscapeOARSI
 
Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
Pathophysiology of Metastatic Bone Disease and the Role of BisphosphonatesPathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonatesshabeel pn
 
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...European School of Oncology
 
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...European School of Oncology
 
Bases talk for slideshare (atkinson)
Bases talk for slideshare (atkinson)Bases talk for slideshare (atkinson)
Bases talk for slideshare (atkinson)GregAtki
 
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)F. Saad - Highlights of Day 2 breakout sessions (Oncology room)
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)European School of Oncology
 
Incyte INCB39110 study results
Incyte INCB39110 study resultsIncyte INCB39110 study results
Incyte INCB39110 study resultsinnovaderm
 
Abstract - A Comparison of Common Taping Techniques in the Management of Pate...
Abstract - A Comparison of Common Taping Techniques in the Management of Pate...Abstract - A Comparison of Common Taping Techniques in the Management of Pate...
Abstract - A Comparison of Common Taping Techniques in the Management of Pate...Karli Spencer
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
Hepatobiliary tumor board (1)
Hepatobiliary tumor board (1)Hepatobiliary tumor board (1)
Hepatobiliary tumor board (1)madurai
 
Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Sociedad Española de Cardiología
 
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...incucai_isodp
 
Tibial tubercle transposition for patellofemoral malalignment
Tibial tubercle transposition for patellofemoral malalignmentTibial tubercle transposition for patellofemoral malalignment
Tibial tubercle transposition for patellofemoral malalignmentLuca Dei Giudici
 

Similaire à Asbmr Ptn 2008 082008 (20)

2020 OA Vision: Emerging Therapeutics on the OA landscape
2020 OA Vision: Emerging Therapeutics on the OA landscape2020 OA Vision: Emerging Therapeutics on the OA landscape
2020 OA Vision: Emerging Therapeutics on the OA landscape
 
Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
Pathophysiology of Metastatic Bone Disease and the Role of BisphosphonatesPathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
 
ABC1 - R.E. Coleman - Bone metastases
ABC1 - R.E. Coleman - Bone metastases ABC1 - R.E. Coleman - Bone metastases
ABC1 - R.E. Coleman - Bone metastases
 
Alternative Menopausal Hormone Therapies.pdf
Alternative Menopausal Hormone Therapies.pdfAlternative Menopausal Hormone Therapies.pdf
Alternative Menopausal Hormone Therapies.pdf
 
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
 
ECCLU 2011 - N. Clarke - Bone targeted agents
ECCLU 2011 - N. Clarke - Bone targeted agentsECCLU 2011 - N. Clarke - Bone targeted agents
ECCLU 2011 - N. Clarke - Bone targeted agents
 
Seminar 08-12-2007 - bisphosphonate mechanism of action
Seminar 08-12-2007 - bisphosphonate mechanism of actionSeminar 08-12-2007 - bisphosphonate mechanism of action
Seminar 08-12-2007 - bisphosphonate mechanism of action
 
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...
NY Prostate Cancer Conference - F. Saad - Session 7: Predicting toxicity afte...
 
Bases talk for slideshare (atkinson)
Bases talk for slideshare (atkinson)Bases talk for slideshare (atkinson)
Bases talk for slideshare (atkinson)
 
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)F. Saad - Highlights of Day 2 breakout sessions (Oncology room)
F. Saad - Highlights of Day 2 breakout sessions (Oncology room)
 
Incyte INCB39110 study results
Incyte INCB39110 study resultsIncyte INCB39110 study results
Incyte INCB39110 study results
 
Abstract - A Comparison of Common Taping Techniques in the Management of Pate...
Abstract - A Comparison of Common Taping Techniques in the Management of Pate...Abstract - A Comparison of Common Taping Techniques in the Management of Pate...
Abstract - A Comparison of Common Taping Techniques in the Management of Pate...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
Hepatobiliary tumor board (1)
Hepatobiliary tumor board (1)Hepatobiliary tumor board (1)
Hepatobiliary tumor board (1)
 
Mark Sherry - hamstring
Mark Sherry - hamstring Mark Sherry - hamstring
Mark Sherry - hamstring
 
Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?
 
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
 
Beschermt overgewicht tegen fracturen?
Beschermt overgewicht tegen fracturen?Beschermt overgewicht tegen fracturen?
Beschermt overgewicht tegen fracturen?
 
Levosimendan drug discovery and pharmacology
Levosimendan drug discovery and pharmacologyLevosimendan drug discovery and pharmacology
Levosimendan drug discovery and pharmacology
 
Tibial tubercle transposition for patellofemoral malalignment
Tibial tubercle transposition for patellofemoral malalignmentTibial tubercle transposition for patellofemoral malalignment
Tibial tubercle transposition for patellofemoral malalignment
 

Asbmr Ptn 2008 082008

  • 1. Anabolic Response to Skeletal Loading in Mice with Targeted Disruption of Pleiotrophin Gene C. Kesavan and S. Mohan JLP VA Medical Center, Loma Linda Univ Loma Linda, CA, 92357 ASBMR 2008
  • 2.
  • 3. Load Load Good Responder Poor Responder Skeletal Response to Loading Differs in Different Individuals
  • 4. Variation in skeletal response to loading is genetically determined 0.00 5.00 10.00 15.00 20.00 6 7 8 9 Load (N) % Increase in vBMD vs unloaded bone Four point bending device C57BL/6J C3H/HeJ Four point bending Increases BMD in C57BL but not in C3H mice P<0.001 Kesavan et al., 2005 P<0.01
  • 5. ML increases pleiotrophin (PTN) expression-Whole genome microarray analysis PTN signals through β -catenin and PI3K PTN expression level ( arbitrary units) p<0.0001 Xing et al., 2005 PTN/HB-GAM/OSF Syndecan Rprp ζ β -catenin PI3K Proliferation/survival/Migration
  • 6. Time course changes in PTN expression in the loaded bones of C57BL Mice A p<0.05 vs. 2- and 4- days of loading (One-way ANOVA) p<0.05 p<0.001 p<0.0001 Days (Duration) Fold increase in PTN vs. unloaded bones A
  • 7. Greater PTN expression in response to ML in good responder C57BL versus poor responder C3H mice Mean ± SD; N = 6 0 2 4 6 8 10 C57BL C3H Fold increase in PTN vs. unloaded bones P<0.0001 P<0.05 P<0.05
  • 8.
  • 9.
  • 10. Skeletal changes in response to loading in PTN KO and control mice *p<0.05 vs. unloaded bones, N = 7 Percent increase vs. unloaded bones * * * * * *
  • 11. Micro-CT analysis of skeletal response to loading Control PTN KO Unloaded Loaded Mean ± SD, N = 7 BV/TV (%) 3.88 ± 2.6 Tb.N (1/mm) 1.56 ± 0.76 Tb.Th (mm) 0.037 ± 0.0.01 Tb.S (mm) 0.76 ± 0.28 BV/TV (%) 2.81 ± 1.5 Tb.N (1/mm) 1.61 ± 0.36 Tb.Th (mm) 0.036 ± 0.0.01 Tb.S (mm) 0.57 ± 0.21
  • 12. Greater midkine expression in response to ML in PTN KO and Control mice N=6 Fold increase vs. unloaded bones P<0.05 P<0.05 P<0.001
  • 13.
  • 14.
  • 15. Thank you Skeletal Un loading Skeletal Loading